Teva’s Antisense Therapy Meets Phase IIa Endpoint In MS Study
This article was originally published in The Pink Sheet Daily
Product licensed from Antisense Therapeutics is under development for reduction in multiple sclerosis-related brain lesions
You may also be interested in...
The move brings a possible buyout of subsidiary one step closer.
In a creative deal that echoes the strategic tie-up last year between Infinity and Mundipharma, Italian giant Chiesi Farmaceutici is buying a majority stake in Cornerstone Therapeutics, which gets $15.5 million along with U.S. rights for 10 years to Chiesi's marketed lung surfactant Curosurf